Initiation of a multi-center Phase III clinical study in India within 60 days

Customer Profile : A large MNC pharmaceutical company approached MakroCare to initiate and conduct a multi-center clinical study in India. The study contained a very complex protocol. Earliest initiation of study is the key factor for a successful outcome.



Oncology

Indication: NSCLC (Non Small Cell Lung Cancer)

A phase III double blind, randomized study in patients with NSCLC




Optimization of statistical analysis, key to best results!

At times, some clinical data seems insignificant and this might cause loss of highly crucial information and wrong inference about the study. Our statistics team makes sure that such data is not overlooked and is further exploited to yield optimum results.